Avenzo collects another $60M for two small molecules and two ADCs licensed from China September 22, 2025
Evommune Presents Full Phase 2 Data for Oral MRGPRX2 Inhibitor EVO756 in Chronic Inducible Urticaria During Late-Breaker at EADV 2025 Congress September 19, 2025
TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025 September 18, 2025
Solu Developing a Powerful New Therapeutic Modality that Unlocks Cell Surface Targets September 12, 2025
